Biotechnology

Radius Health & Menarini Group Provide Elacestrant Update

Target enrollment milestone reached in the Phase 3 EMERALD study Life cycle planning advancing in parallel with current Phase 3 monotherapy program WALTHAM, Mass. and FLORENCE, Italy, Sept. 25, 2020 /PRNewswire/ -- -Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) and the Menari...

2020-09-25 18:15 3437

Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by U.S. FDA

NEWARK, Del., Sept. 24, 2020 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth") today announced that its leading candidate, NR082 (rAAV2-ND4, NFS-01 project), was granted an orphan drug designation (ODD) by the U.S. FDA for the treatment of Leber's Hereditary O...

2020-09-25 10:37 751

Cell Signaling Technology Named a Top Charitable Company in Massachusetts by the Boston Business Journal

DANVERS, Massachusetts, Sept. 24, 2020 /PRNewswire/ -- Cell Signaling Technology, Inc. (CST), a discovery technology company and leading provider of antibodies, kits, and services, was named by the Boston Business Journal (BBJ) for the 5th year in a row, as a 2020 top corporate charitable contrib...

2020-09-24 20:00 1522

KYAN Therapeutics Exclusively Licenses Small Molecule HDAC Inhibitors for AI-Powered Cancer Drug Development

SINGAPORE, Sept. 24, 2020 /PRNewswire/ -- KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors. KYAN has...

2020-09-24 17:12 829

Macrogen, K-Quarantine System "Smart Mobile Lab" Exported to Indonesia

SEOUL, South Korea, Sept. 24, 2020 /PRNewswire/ -- Macrogen has established the first "Smart Mobile Lab" in Korea and has supplied it toIndonesia as well. Macrogen has established the first “Smart Mobile Lab” in Korea and has supplied it to ...

2020-09-24 09:00 1275

SEMI-NBMC Invites White Paper Proposals for Funding of Human Monitoring Innovations

MILPITAS, California, Sept. 23, 2020 /PRNewswire/ -- SEMI Nano-Bio Materials Consortium (NBMC) today released a Request for Proposals (RFP) for innovations in ambulatory monitoring, wearable technologies for cognitive assessment, and innovative power sources for wearable monitors. Proposals are a...

2020-09-24 07:11 1180

ImmVira Announces US$10 million Strategic Series B Plus Financing with SIIC Capital

SHENZHEN and SHANGHAI, Sept.23, 2020 /PRNewswire/ -- ImmVira Group Company, a biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics today announced signing ofUS$10 million Series B Plus strategic financing. This round of financing wi...

2020-09-24 00:09 1246

Insilico releases Pandomics, AI-powered platform for Novel Therapeutic Target Discovery

A novel end-to-end AI-hypothesis generation engine that seamlessly interprets OMICS and text-based data for the discovery and analysis of novel therapeutic targets HONG KONG, Sept. 23, 2020 /PRNewswire/ -- Insilico Medicine announces the official release ofPandomics - a part of the Pharma.ai AI ...

2020-09-23 22:00 1824

Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate

NEW BRUNSWICK, New Jersey, Sept. 23, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Com...

2020-09-23 19:25 2890

Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau

* Minoryx will receive an upfront and milestone payments of up to $78 million , as well as double digit royalties on annual net sales * Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-th...

2020-09-23 15:00 672

Cosmo PR and HekaBio Announce Strategic Partnership and Investment in HekaBio

TOKYO, Sept. 22, 2020 /PRNewswire/ -- HekaBio K.K. (hereafter: HekaBio) and Cosmo Public Relations Corporation (hereafter:Cosmo) have announced that Cosmo has made an investment in HekaBio and that the companies have entered into a strategic partnership to increase awareness of and accessibility ...

2020-09-23 09:00 890

Eurisotop Responds to Market Demand for Deuterated Chloroform

SACLAY, France, Sept. 22, 2020 /PRNewswire/ -- Eurisotop, a wholly owned subsidiary of Cambridge Isotope Laboratories, Inc. (CIL), announced a capacity expansion of its deuterated chloroform production. Since its acquisition by CIL in 2001, Eurisotop has become a leading producer of deuterated NM...

2020-09-22 22:00 1533

Jennewein Biotechnologie GmbH and Chr. Hansen A/S to join forces in high-growth Human Milk Oligosaccharides market

RHEINBREITBACH and BONN, Germany, Sept. 22, 2020 /PRNewswire/ -- Jennewein Biotechnologie GmbH agreed to join forces with Chr. Hansen Holding A/S, a leading bioscience company based in Hoersholm/Denmark, to lead the global market for human milk oligosaccharides (HMOs). Chr. Hansen entered into an...

2020-09-22 21:36 1889

Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma

SYDNEY, Sept. 22, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into a collaboration with Dana-Farber Cancer Institute (DFCI) inthe United States, to investigate the use of...

2020-09-22 09:21 6546

Samsung Biologics and AstraZeneca forge strategic manufacturing partnership for global supply

INCHEON, South Korea, Sept. 21, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million. Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Pla...

2020-09-22 07:00 7872

PharmAbcine expands partnership with Samsung Biologics for PMC-403

DAEJEON, South Korea, Sept. 21, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Samsung Biologics (KRX: 207940.KS) for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular ...

2020-09-21 20:00 1027

Key Milestone: The first patient successfully dosed with the candidate drug SR419 for peripheral neuropathic pain

SHANGHAI, Sept. 21, 2020 /PRNewswire/ -- Shanghai SIMR Biotechnology Co., Ltd. (hereinafter referred to as "SIMR" or "Company") announced that, the clinical trial in patients with peripheral neuropathic pain has been initiated for the candidate drug SR419, and the first patient has been successfu...

2020-09-21 10:35 886

Apis Partners leads US$15 million investment in Prenetics

* Investment will go into game-changing rapid COVID-19 test, highly accurate, results in 15-30 minutes, no lab required, low-cost. In discussions with Governments globally. * Enabling Travel Bubble: Prenetics, Cathay Pacific to launch pilot in October 2020 from HKG to LHR with The Commons Pro...

2020-09-18 08:00 3517

Expanding Their Existing Strategic Collaboration, GenScript ProBio Licensed Global Rights to Develop and Commercialize a SMAB Bispecific Antibody Molecule to REMD Biotherapeutics Inc.

NANJING, China, Sept. 17, 2020 /PRNewswire/ -- On September 16th, 2020, GenScript ProBio and REMD Biotherapeutics Inc. (REMD) announced that REMD has licensed a bispecific antibody derived from the Single-domain antibody fused to Monoclonal Ab (SMAB) platform developed by GenScript ProBio. REMD i...

2020-09-17 22:00 1232

Viva Biotech's Portfolio Company Dogma Therapeutics Reached the Acquisition Agreement with AstraZeneca on Dogma's Oral PCSK9 Inhibitor Program

CAMBRIDGE, Mass., Sept. 17, 2020 /PRNewswire/ -- Dogma Therapeutics ("Dogma"), a Viva Biotech Portfolio Company, has reached an agreement for the acquisition of its oral PCSK9 program by AstraZeneca. Dogma will receive upfront as well as downstream payments linked to global regulatory and commerc...

2020-09-17 20:25 2416
12345 ... 178